MedTrace Logo

Effect of SGLT-2 Inhibitors in Patients With T2DM and Moderate to Severe Liver Fibrosis

NCT05943899 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2023-07-17

No results posted yet for this study

Summary

This retrospective study will be of 12 months duration where 40 T2DM patients coming to FORTIS C-DOC hospital in OPD with F3 fibrosis will be included in the study. The population will be representative of different socio-economic strata of the society. Clinical and dietary profiles, phenotypic markers (acanthosis nigricans, buffalo hump, skin tags, xanthelasma, double chin, arcus, hirsutism) anthropometric assessments body mass index; biochemical markers like liver function test, HbA1c, prothrombin time/INR, and fibroscan will be assessed.

Conditions

  • Type2diabetes

Sponsors & Collaborators

  • National Diabetes Obesity and Cholesterol Foundation

    collaborator OTHER

  • Diabetes Foundation, India

    lead OTHER

Principal Investigators

  • Anoop Misra, MD · Fortis CDOC Hospital

Eligibility

Min Age
25 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-02-01
Primary Completion
2022-12-31
Completion
2023-06-30

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05943899 on ClinicalTrials.gov